Financial Enhancement Group LLC Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA

Financial Enhancement Group LLC purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 31,391 shares of the company’s stock, valued at approximately $2,007,000.

Several other hedge funds and other institutional investors have also bought and sold shares of KNSA. Amundi acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after buying an additional 1,002 shares in the last quarter. Millennium Management LLC raised its position in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares in the last quarter. Creative Planning bought a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $358,000. Finally, Quantbot Technologies LP bought a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Up 3.5%

Shares of Kiniksa Pharmaceuticals International stock opened at $75.99 on Wednesday. The company has a 50 day moving average of $59.91 and a 200-day moving average of $51.70. Kiniksa Pharmaceuticals International, plc has a 1-year low of $31.78 and a 1-year high of $82.94. The company has a market cap of $5.85 billion, a PE ratio of 78.34 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The business had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. Research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.38 earnings per share for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the sale, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 51.98% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Citigroup increased their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $87.38.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.